Regeneron Pharmaceuticals (NQ:REGN)

735.20 +0.39 (+0.05%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

66 67 Next >

Regeneron Pharmaceuticals Slumps As Sales Of High-Dose Eylea Disappoint ↗

January 13, 2025

The company is also facing off with biosimilars for standard Eylea and competition with Roche.

Via Investor's Business Daily

Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

January 13, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial

January 13, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery

January 13, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Forecasting The Future: 22 Analyst Projections For Regeneron Pharmaceuticals ↗

January 10, 2025

Via Benzinga

What Analysts Are Saying About Regeneron Pharmaceuticals Stock ↗

January 08, 2025

Via Benzinga

REGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

January 13, 2025

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

January 10, 2025

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel

January 10, 2025

From DiCello Levitt LLP

Via GlobeNewswire

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today ↗

December 23, 2024

Via Benzinga

Law Offices of Howard G. Smith Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action

January 10, 2025

From Law Offices of Howard G. Smith

Via Business Wire

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference ↗

January 09, 2025

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Via Benzinga

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

What 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals ↗

December 17, 2024

Via Benzinga

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

January 08, 2025

From The Schall Law Firm

Via Business Wire

Stockholder Notice: Robbins LLP Informs Stockholders of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit

January 08, 2025

From Robbins LLP

Via GlobeNewswire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals

January 08, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

Law Offices of Frank R. Cruz Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action

January 08, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

REGENERON THERAPEUTICS, INC. (NASDAQ: REGN) INVESTOR ALERT: Investors With Large Losses in Regeneron Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

January 08, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

REGN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of Regeneron Pharmaceuticals, Inc. Investors

January 07, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

January 07, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

January 07, 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

Via MarketBeat

1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street ↗

January 02, 2025

Via The Motley Fool

Healthcare And Biotech Stocks Continue Their Slide ↗

December 30, 2024

Biotech shares continued their slide which began in early November and got no help from small caps which also sold off through December.

Via Talk Markets

Topics ETFs Stocks / Equities

Are You Ready To Trade Biotech Stocks At The Cusp Of A Bear Market? ↗

December 23, 2024

It’s not a bear market for biotech yet it just feels that way because recent trends are down and healthcare stocks are not a stabilizing force.

Via Talk Markets

Topics ETFs Stocks / Equities

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More ↗

December 22, 2024

JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.

Via Benzinga

Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results

December 19, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

December 17, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study ↗

December 17, 2024

Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA submission expected in Q1 2025.

Via Benzinga

Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts ↗

December 17, 2024

Wall Street began Tuesday’s session on a weaker note, with major indices slipping after November's robust retail sales report reignited investor concerns that the Federal Reserve might hold back...

Via Benzinga

Topics Economy

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

66 67 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.